PMO Interview with the Innovator Series: Volume 2
Peter Hirth, PhD
Video Categories: PMO Interview with the Innovator Series
The publishers of Personalized Medicine in Oncology (PMO) invite you to watch an interview with Peter Hirth, PhD, Chief Executive Officer of Plexxikon. In part one, Dr. Hirth discusses the use of biomarkers, segmenting the population of melanoma patients into subsets, and other aspects of personalized medicine.
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the circumstances in which they would use the Breast Cancer IndexSM (BCI) to assist in determining whether to extend the adjuvant therapy of women with breast cancer beyond 5 years.
Dr. Stainthorpe explains that when it comes to bringing personalized medicines to fruition, the challenge is the same worldwide. It is an effort that requires better understanding of disease pathways and markers as well as improved diagnostics.